<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>COLY-MYCIN  M- colistimethate sodium injection </strong><br>JHP Pharmaceuticals LLC<br></p></div>
<h1>Coly-Mycin® M Parenteral (Colistimethate for Injection, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Coly-Mycin M and other antibacterial drugs, Coly-Mycin M should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
<p><span class="Bold">FOR INTRAMUSCULAR AND INTRAVENOUS USE</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Coly-Mycin® M Parenteral (Colistimethate for Injection, USP) is a sterile parenteral antibiotic product which, when reconstituted (see <span class="Bold"><a href="#Reconstitution">Reconstitution</a></span>), is suitable for intramuscular or intravenous administration.</p>
<p>Each vial contains colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity). </p>
<p>Colistimethate sodium is a polypeptide antibiotic with an approximate molecular weight of 1750. The empirical formula is C<span class="Sub">58</span>H<span class="Sub">105</span>N<span class="Sub">16</span>Na<span class="Sub">5</span>O<span class="Sub">28</span>S<span class="Sub">5</span> and the structural formula is represented below:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d6e13e2-dc33-4b7b-84d0-66146a57c552&amp;name=coly-mycin-01.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Typical serum and urine levels following a single 150 mg dose of Coly-Mycin M Parenteral IM or IV in normal adult subjects are shown in Figure 1.</p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d6e13e2-dc33-4b7b-84d0-66146a57c552&amp;name=coly-mycin-02.jpg"></p>
<p>Higher serum levels were obtained at 10 minutes following IV administration. Serum concentration declined with a half-life of 2–3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.</p>
<p>Average urine levels ranged from about 270 mcg/mL at 2 hours to about 15 mcg/mL at 8 hours after intravenous administration and from 200 to about 25 mcg/mL during a similar period following intramuscular administration.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Colistimethate sodium is a surface active agent which penetrates into and disrupts the bacterial cell membrane. It has been shown to have bactericidal activity against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#IU">INDICATIONS AND USAGE</a></span> section:</p>
<p><span class="Bold">Aerobic gram-negative microorganisms:</span> Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Susceptibility Tests</h2>
<p class="First">Colistimethate sodium is no longer listed as an antimicrobial for routine testing and reporting by clinical microbiology laboratories. 										</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IU"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Coly-Mycin M Parenteral is indicated for the treatment of acute or chronic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to sensitive <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of certain gram-negative bacilli. It is particularly indicated when the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is caused by sensitive <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas aeruginosa</span>. This antibiotic is not indicated for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Proteus</span> or <span class="Italics">Neisseria</span>. Coly-Mycin M Parenteral has proven clinically effective in treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to the following gram-negative organisms: <span class="Italics">Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. </span></p>
<p>Coly-Mycin M Parenteral may be used to initiate therapy in serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are suspected to be due to gram-negative organisms and in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible gram-negative pathogenic bacilli.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Coly-Mycin M and other antibacterial drugs, Coly-Mycin M should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">The use of Coly-Mycin M Parenteral is contraindicated for patients with a history of sensitivity to the drug or any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Maximum daily dose calculated from colistin base activity should not exceed 5 mg/kg/day with normal renal function.</p>
<p>Transient neurological disturbances may occur. These include <span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">circumoral paresthesia</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4034686" conceptname="Formication">formication</span> of the extremities, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">generalized pruritus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and slurring of speech. For these reasons, patients should be warned not to drive vehicles or use hazardous machinery while on therapy. Reduction of dosage may alleviate symptoms. Therapy need not be discontinued, but such patients should be observed with particular care.</p>
<p><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> can occur and is probably a dose-dependent effect of colistimethate sodium. These manifestations of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> are reversible following discontinuation of the antibiotic.</p>
<p>Overdosage can result in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (see <span class="Bold"><a href="#OD">OVERDOSAGE</a></span> section). See <span class="Bold"><a href="#PreDI">PRECAUTIONS, Drug Interactions</a></span> subsection for use concomitantly with other antibiotics and curariform drugs.</p>
<p><span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">Respiratory arrest</span> has been reported following intramuscular administration of colistimethate sodium. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span> increases the possibility of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> and <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> following administration of colistimethate sodium. Therefore, it is important to follow recommended dosing guidelines. See <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span> section for use in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Coly-Mycin M Parenteral, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Since Coly-Mycin M Parenteral is eliminated mainly by renal excretion, it should be used with caution when the possibility of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> exists. The decline in renal function with advanced age should be considered.</p>
<p>When actual <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is present, Coly-Mycin M Parenteral may be used, but the greatest caution should be exercised and the dosage should be reduced in proportion to the extent of the impairment. Administration of amounts of Coly-Mycin M Parenteral in excess of renal excretory capacity will lead to high serum levels and can result in further impairment of renal function, initiating a cycle which, if not recognized, can lead to <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal insufficiency</span>, renal shutdown, and further concentration of the antibiotic to toxic levels in the body. At this point, interference of nerve transmission at neuromuscular junctions may occur and result in <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (see <span class="Bold"><a href="#OD">OVERDOSAGE</a></span> section).</p>
<p>Signs indicating the development of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> include: diminishing urine output, rising BUN and serum creatinine and decreased creatinine clearance. Therapy with Coly-Mycin M Parenteral should be discontinued immediately if signs of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> occur. However, if it is necessary to reinstate the drug, dosing should be adjusted accordingly after drug plasma levels have fallen (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span> section).</p>
<p>Prescribing Coly-Mycin M in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="PreDI"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. Based on this reported activity, they should not be given concomitantly with Coly-Mycin M Parenteral except with the greatest caution.</p>
<p>Curariform muscle relaxants (e.g., tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.</p>
<p>Sodium cephalothin may enhance the <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> of Coly-Mycin M Parenteral. The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal carcinogenicity studies and genetic toxicology studies have not been performed with colistimethate sodium. There were no adverse effects on fertility or reproduction in rats at doses of 9.3 mg/kg/day (0.30 times the maximum daily human dose when based on mg/m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Colistimethate sodium given intramuscularly during organogenesis to rabbits at 4.15 and 9.3 mg/kg resulted in <span class="product-label-link" type="condition" conceptid="4134730" conceptname="Talipes">talipes</span> varus in 2.6% and 2.9% of fetuses, respectively. These doses are 0.25 and 0.55 times the maximum daily human dose based on mg/m<span class="Sup">2</span>. In addition, increased resorption occurred at 9.3 mg/kg. Colistimethate sodium was not teratogenic in rats at 4.15 or 9.3 mg/kg. These doses are 0.13 and 0.30 times the maximum daily human dose based on mg/m<span class="Sup">2</span>. There are no adequate and well-controlled studies in pregnant women. Since colistimethate sodium is transferred across the placental barrier in humans, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether colistimethate sodium is excreted in human breast milk. However, colistin sulphate is excreted in human breast milk. Therefore, caution should be exercised when colistimethate sodium is administered to nursing women.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of colistemethate sodium did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">In clinical studies, colistimethate sodium was administered to the pediatric population (neonates, infants, children and adolescents). Although adverse reactions appear to be similar in the adult and pediatric populations, subjective symptoms of toxicity may not be reported by pediatric patients. Close clinical monitoring of pediatric patients is recommended.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.8"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Coly-Mycin M should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Coly-Mycin M is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Coly-Mycin M or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported:</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span></p>
<p><span class="Bold">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of extremities and tongue, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p>
<p><span class="Bold">Integumentary:</span> <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">generalized itching</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></p>
<p><span class="Bold">Laboratory Deviations:</span> increased blood urea nitrogen (BUN), elevated creatinine and decreased creatinine clearance</p>
<p><span class="Bold">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span></p>
<p><span class="Bold">Renal System:</span> <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and decreased urine output</p>
<p>For medical advice about adverse reactions contact your medical professional.  To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OD"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage with colistimethate sodium can cause <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> characterized by <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, disorders of speech and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Respiratory muscle <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> may lead to <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Overdosage with the drug can also cause <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, manifested as decreased urine output and increases in serum concentrations of BUN and creatinine.</p>
<p>As in any case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, colistimethate sodium therapy should be discontinued and general supportive measures should be utilized.</p>
<p>It is unknown whether colistimethate sodium can be removed by hemodialysis or peritoneal dialysis in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Important:</span> Coly-Mycin M Parenteral is supplied in vials containing colistimethate sodium equivalent to 150 mg colistin base activity per vial.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Reconstitution"></a><a name="section-10.1"></a><p></p>
<h2>Reconstitution for Intravenous or Intramuscular Administration</h2>
<p class="First">The <span class="Bold">150 mg</span> vial should be reconstituted with <span class="Bold">2 mL</span> Sterile Water for Injection, USP. The reconstituted solution provides colistimethate sodium at a concentration equivalent to 75 mg/mL colistin base activity.</p>
<p>During reconstitution swirl <span class="Bold">gently</span> to avoid frothing.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If these conditions are observed, the product should not be used.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<h3>Adults and Pediatric Patients—Intravenous or Intramuscular Administration</h3>
<p class="First">The dose of Coly-Mycin M Parenteral should be  2.5 to 5 mg/kg per day of colistin base in 2 to 4 divided doses for patients with normal renal function, depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>In obese individuals, dosage should be based on ideal body weight.</p>
<p>The daily dose and frequency should be reduced for the patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Suggested modifications of dosage schedule for patients with  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are presented in Table 1.</p>
<table width="100%">
<caption><span>TABLE 1.	Suggested Modification of Dosage Schedules of Coly-Mycin M Parenteral for Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center" colspan="4">Degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">Normal</th>
<th class="Lrule" align="center">Mild</th>
<th class="Lrule" align="center">Moderate</th>
<th class="Lrule Rrule" align="center">Severe</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top">Note:  The suggested total daily dose is calculated from colistin base activity.</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Creatinine Clearance (mL/min)</td>
<td class="Rrule" align="center">≥80</td>
<td class="Rrule" align="center">50-79</td>
<td class="Rrule" align="center">30-49</td>
<td class="Rrule" align="center">10-29</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Dosage Schedule</td>
<td class="Rrule" align="left">2.5 – 5 mg/kg, divided into 2 to 4 doses per day</td>
<td class="Rrule" align="left">2.5 – 3.8 mg/kg, divided into 2 doses per day</td>
<td class="Rrule" align="left">2.5 mg/kg, once daily or divided into 2 doses per day</td>
<td class="Rrule" align="left">1.5 mg/kg every 36 hours</td>
</tr>
</tbody>
</table>
<table width="75%">
<col align="left" valign="top" width="100%">
<tbody class="Headless">
<tr class="First"><td class="Lrule Rrule" align="left"><span class="Bold">INTRAVENOUS ADMINISTRATION</span></td></tr>
<tr><td class="Lrule Rrule" align="left">
<ol>
<li>Direct Intermittent Administration—Slowly inject one-half of the total daily dose over a period of 3 to 5 minutes every 12 hours.</li>
<li>Continuous Infusion—Slowly inject one-half of the total daily dose over 3 to 5 minutes. Add the remaining half of the total daily dose of Coly-Mycin M Parenteral to one of the following:<br>0.9% NaCI<br>5% dextrose in 0.9% NaCI<br>5% dextrose in water<br>5% dextrose in 0.45% NaCI<br>5% dextrose in 0.225% NaCI<br>lactated Ringer's solution<br>10% invert sugar solution</li>
</ol>
<p class="First">There are not sufficient data to recommend usage of Coly-Mycin M Parenteral with other drugs or other than the above listed infusion solutions.</p>
<p>Administer the second half of the total daily dose by slow intravenous infusion, starting 1 to 2 hours after the initial dose, over the next 22 to 23 hours. In the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, reduce the infusion rate depending on the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>The choice of intravenous solution and the volume to be employed are dictated by the requirements of fluid and electrolyte management.</p>
<p><span class="Bold">Any final intravenous infusion solution containing colistimethate sodium should be freshly prepared and used for no longer than 24 hours.</span></p>
</td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">INTRAMUSCULAR ADMINISTRATION</span></td></tr>
<tr><td class="Lrule Rrule" align="left"><ol class="Arabic"><li>For intramuscular Injection, administer by deep intramuscular injection into a large <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span> (such as the gluteal muscles or lateral part of the thigh).</li></ol></td></tr>
<tr class="Last"><td class="Lrule Rrule" align="left"><span class="Bold Underline">Store reconstituted solution for intramuscular injection in a refrigerator 2° to 8°C (36° to 46°F) or between 20° to 25°C (68° to 77°F) and use within 7 days.</span></td></tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Coly-Mycin M Parenteral is supplied in vials containing colistimethate sodium (equivalent to 150 mg colistin base activity per vial) as a white to slightly yellow Iyophilized cake.</p>
<p>NDC 42023-107-01:  one individual vial.<br>NDC 42023-107-06:  six vials per carton.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Store between 20° to 25°C (68° to 77°F).  (See USP controlled room temperature.)</span></p>
<p><span class="Bold">Store reconstituted solution in refrigerator 2° to 8°C (36° to 46°F) or between 20° to 25°C (68° to 77°F) and use within 7 days.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Rx only.</span></p>
<p>Prescribing information as of March 2013.</p>
<p>Manufactured and Distributed by:<br>JHP Pharmaceuticals, LLC<br>Rochester, MI 48307</p>
<p>3000818G</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg Vial Carton</h1>
<p class="First"><span class="Bold">NDC</span> 42023-107-01</p>
<p><span class="Bold">Coly-Mycin<span class="Sup">®</span> M<br>Parenteral</span><br>(Colistimethate for<br>Injection, USP</p>
<p><span class="Bold">150 mg<br>Colistin base<br>activity</span></p>
<p><span class="Bold">For Intramuscular and <br>Intravnous Use</span></p>
<p><span class="Bold">Rx</span> Only</p>
<p><span class="Bold">1 Vial</span></p>
<p><span class="Bold">JHP<br>PHARMACEUTICALS</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 150 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d6e13e2-dc33-4b7b-84d0-66146a57c552&amp;name=coly-mycin-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COLY-MYCIN 		
					 M</strong><br><span class="contentTableReg">colistimethate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42023-107</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>colistimethate sodium</strong> (colistimethate) </td>
<td class="formItem">Colistin</td>
<td class="formItem">150 mg  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42023-107-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:42023-107-06</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050108</td>
<td class="formItem">11/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>JHP Pharmaceuticals LLC
							(804894611)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d5e27b02-6369-4e73-a45e-27b07be53b23</div>
<div>Set id: 6d6e13e2-dc33-4b7b-84d0-66146a57c552</div>
<div>Version: 8</div>
<div>Effective Time: 20130401</div>
</div>
</div> <div class="DistributorName">JHP Pharmaceuticals LLC</div></p>
</body></html>
